Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6423575 | 0.94 | AKR1C3 (0.55) | PTGS2AKR1C3AKR1C2PTGS1HRH4 | |
| SCHEMBL6425901 | 0.92 | PTGS2 (0.54) | PTGS2AKR1C3AKR1C2PTGS1MAPT | |
| SCHEMBL5554745 | 0.92 | PTGS2 (0.50) | PTGS2AKR1C3AKR1C2PTGS1HRH4 | |
| SCHEMBL5798232 | 0.91 | PTGS2 (0.59) | PTGS2AKR1C3AKR1C2PTGS1MAPT | |
| SCHEMBL5554740 | 0.91 | AKR1C3 (0.58) | PTGS2AKR1C3AKR1C2PTGS1HRH4 | |
| SCHEMBL6426638 | 0.90 | PTGS2 (0.44) | PTGS2AKR1C3AKR1C2PTGS1MAPT | |
| SCHEMBL5559380 | 0.90 | PTGS2 (0.61) | PTGS2AKR1C3AKR1C2PTGS1MAPT | |
| SCHEMBL5554578 | 0.90 | AKR1C3 (0.55) | PTGS2AKR1C3AKR1C2PTGS1MAPT | |
| SCHEMBL6425842 | 0.90 | PTGS2 (0.59) | PTGS2AKR1C3AKR1C2PTGS1MAPT | |
| SCHEMBL6426437 | 0.90 | PTGS2 (0.52) | PTGS2AKR1C3AKR1C2PTGS1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | PTGS2 4/4885AKR1C3 577/4885AKR1C2 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.